Psoriatic,arthritis:combinational,therapy,of,biologics,and,methotrexate,-,What,do,we,know?
Stephanie Dauth ,Michaela Köhm ,Frank Behrens
1 Fraunhofer Institute for Molecular Biology and Applied Ecology (IME),Branch for Translational Medicine and Pharmacology,Frankfurt am Main,Germany
2 Fraunhofer Cluster of Excellence Immune-mediated Diseases CIMD,Frankfurt am Main,Germany
3 Rheumatology Department,University Hospital,Frankfurt am Main,Germany
Abstract
Key words:biological therapy;
combinational therapy;
methotrexate;
psoriatic arthritis;
ustekinumab
Psoriatic arthritis (PsA) is a systemic inflammatory disease characterized by musculoskeletal involvement mostly associated with skin psoriasis.Usually,skin disease is diagnosed years before musculoskeletal involvement appears.The heterogeneous clinical features of PsA include peripheral arthritis(oligo or polyarthritis),inflammatory spine disease,enthesitis,dactylitis as well as skin and nail psoriasis.1Furthermore,associated extra-musculoskeletal features such as uveitis and gut inflammation could be present.The heterogeneous spectrum of clinical features in PsA is reflected in its complex pathogenesis:both genomic and environmental triggers are named to interfere with the innate and acquired immune system.1-3
PsA is associated with significant morbidity and disability,and thus constitutes a major socioeconomic burden.It is not only more common but also more severe than previously thought.1,2By the time patients present to a PsA clinic,67%have at least one joint with erosion.4Over 10 years of followup,55% of the patients have at least five clinically damaged joints.5Even in early disease,of 129 patients seen within 5 months of symptom onset in an early arthritis clinic,47%developed erosions within the first 2 years.6The diagnosis of PsA is often delayed or missed,partly because patients may present with inflammatory spinal pain,tendinitis,enthesitis,or dactylitis rather than a “true arthritis”.If PsA is not identified early and managed appropriately,progressive joint damage with deformities and disability may result.Early sufficient treatment results in better outcome.7-9
For therapeutic strategies,early diagnosis and sufficient treatment lead to the best outcome with prevention of structural damage (osteoproliferative and erosions) and loss of function.First-line treatments of PsA that are chosen according to international guidelines,are,after failure of non-steroidal anti-inflammatory drugs (NSAIDs),conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) such as methotrexate (MTX).10Therapy with csDMARDs is limited due to their relatively low effect size,as well as their tolerability and safety profile:approximately 55% of patients must be escalated to the second-line treatment according to treatment recommendations.11Several randomized clinical trials (RCTs)have proven the efficacy of tumour necrosis factor-inhibitors(TNFi),such as adalimumab (ADA),infliximab (INF) or golimumab (GOL),after failure of csDMARD-therapies for PsA.1,12However,a percentage of PsA patients do not respond to TNFi-therapy,emphasizing the need for additional treatment modalities with distinct mechanisms of action.
In clinical routine care as well as in clinical studies,it is important to reliably evaluate disease activity.PsA is a heterogeneous disease with the possible involvement of several domains,which makes diagnosis and reliable evaluations challenging.There are several disease activity assessments,which are available and commonly used:examination of 68 joints for tenderness and 66 joints for swelling,pain,enthesitis,and dactylitis.In addition,several skin specific assessments and composite scores for skin manifestation are available and commonly used:Psoriasis Area and Severity Index,involvement of nails,and involved body-surface area.Single assessments such as pain intensity or swollen and tender joints can then be implemented into a composite score to evaluate disease activity.Examples include the disease activity score 28 (DAS28)that includes swollen and tender joints (subset of 28 joints),C-reactive protein or erythrocyte sedimentation rate and patients" assessment of disease activity or the Leeds enthesitis index score as an assessment for severity of enthesitis.1In clinical trials,outcome measures and composite scores known for rheumatoid arthritis (RA) are used for PsA as well,such as the DAS28 or American College of Rheumatology (ACR)20,50 and 70 response rates.The latter indicates reduction in the number of tender and swollen joints of at least 20%,50% or 70%,with improvement in at least three of five additional parameters:patient and physician global assessments,pain,disability,and an acute phase-reactant (e.g.,C-reactive protein).1,11
The authors used the following inclusion criteria for this non-systematic review:clinical studies that discussed the concomitant use of methotrexate (or DMARDs) with biological treatments.English language and full-text articles published between 2005 and 2019 were included.Participants were males and females above the age of 18 years with a clinical diagnosis of psoriatic arthritis.The authors searched the PubMed database to identify relevant publications.The literature search strategy was conducted with the following key words or combinations thereof:psoriatic arthritis,concomitant methotrexate,biologics/biological therapy/biological treatment,etanercept,tofacitinib,adalimumab,infliximab,apremilast,golimumab,TNF inhibitors,ixekizumab,secukinumab,and ustekinumab(UST).The authors also screened the reference list of included studies to identify other potentially useful studies.The data extraction process focused on the information about each study type,the indication and the applied therapy.
MTX therapy plays a key role in the treatment of RA and PsA,even in the age of biologic therapies:In the national and international therapy recommendations,MTX as csDMARD is part of the first-line therapy of both diseases if there are no contraindications against its clinical use.13,14Reasons for the early use of MTX are the proof of clinical efficacy in RA,its potential to decelerate radiographic progression in RA and that there is no data that the use of biologics instead of MTX brings significant advantages at the time of RA diagnosis.15Even if MTX therapy is no longer sufficient in the course of the disease and other DMARDs (such as leflunomide or biologics) are used,therapy with MTX is usually continued as a combination partner in the treatment of RA,but often also in the treatment of PsA.16In RA treatment,MTX therapy is usually continued as concomitant medication to biologic therapy,as this combinational therapy has shown to be efficacious with e.g.,INF,etanercept (ETA),ADA and GOL.12In addition,MTX has a synergistic and inhibitory effect on the formation of anti-drug antibodies.17Treatment options for PsA have historically mirrored those of RA;
therefore,MTX is often used as the first drug of choice in PsA as well.However,despite MTX being one of the most commonly used drugs in PsA after NSAIDs,few data are available from RCTs to indicate its efficacy.12
The combination of biologics (e.g.,TNFi) and MTX shows a significantly stronger clinical effect than biologic monotherapy in the treatment of RA.However,the influence of MTX on the biologic therapy of PsA remains questionable,due to the lack of data from RCTs.Registration studies are only able to show that the addition of biologic therapy to MTX (i.e.,inadequate response to MTX alone) or to NSAIDs (i.e.,inadequate response to NSAIDs;
no concomitant MTX) in patients with active PsA achieves a comparable clinical improvement.Currently available data,mostly as analyses from subgroups of regulatory studies,from registry data or data from noninterventional studies are controversially discussed (Table1).For most biological therapies,it remains unclear whether MTX naive patients benefit more from the combination of MTX and biologic treatment than from biologic monotherapy and whether MTX patients receiving biologic therapy clinically worsen when MTX is discontinued.At least for ETA part of this question was answered with a recent randomized,controlled clinical trial that showed similar clinical results in PsA patients receiving combination therapy (ETA/MTX) and ETA monotherapy (details below).18
Overall,the efficacy of concomitant MTX use with biologics does not seem to differ from that of biologic monotherapy in PsA,but the combination therapy tends to show a lower side effect rate in PsA patients.12,19
Fragerli et al.20demonstrated no superiority in the efficacy of the TNFi/MTX combination therapy compared to biologic monotherapy,measured by DAS28 and ACR/EULAR response.56.1%,40.9% and 24.2% of PsA patients with TNFi monotherapy achieved ACR20,50 and 70 after 6 months.In the combination therapy group (TNFi/MTX),the rates were 59.6%,36.2%,and 26.2%.EULAR remission was 44.1%(TNFi monotherapy) and 46.6% (TNFi/MTX) after 6 months.20
Table1:Selected studies with data regarding concomitant MTX to biologic treatment or targeted basic therapeutics
A prospective Swedish study with 261 PsA patients found no differences in the number of painful and swollen joints or in the evaluation of pain during the study comparing TNFi monotherapy and TNFi/MTX combination therapy.21Other studies with TNFi also showed no additional improvement in clinical response (ACR response) with concomitant MTX.22-24
ADALIMUMAB
Two studies with ADA with/without concomitant MTX therapy showed that combination therapy (ADA/MTX) in PsA patients led to a comparable clinical efficacy and radiographic progression reduction compared to ADA alone.24,2555%,36%,and 17% of PsA patients with ADA/MTX therapy achieved ACR20,50,and 70 at week 12 compared to 61%,36%,and 23% with ADA monotherapy.24Gladman et al.25reported that the ACR values were numerically greater for patients with MTX combination therapy compared to ADA monotherapy,but a significant difference was not achieved.50%,38%,and 29% of patients with ADA monotherapy achieved ACR 20,50,and 70 at week 48 compared to 63%,49%,and 31% with combination therapy.
The clinical response to ADA monotherapy compared to ADA/MTX combination therapy in a study by Behrens et al.26was almost the same.In this analysis,PsA patients with and without axial involvement were evaluated,since MTX is certainly ineffective for axial manifestation.Therefore,a potential positive effect should be evident especially in patients without spinal involvement.After 24 months,patients with axial PsA showed a DAS28 change of -1.9 (ADA monotherapy) and-2.2 (ADA/MTX) and patients without axial manifestation of-2.2 (both treatment groups).Accompanying MTX therefore has no effect on joint results in PsA patients who begin ADA therapy,regardless of axial involvement.26
ETANERCEPT
Mease et al.18recently completed a multicenter,double-blind,randomized,controlled trial to compare the efficacy and safety of ETA/MTX combination therapy with ETA or MTX monotherapy in MTX-naive PsA patients.The study enrolled 851 PsA patients.Primary endpoint was the clinical efficacy at week 24 measured by the ACR20 response.50.7% of patients with MTX monotherapy achieved ACR20 response at week 24,60.9% of patients in the ETA group,and 65% in the ETA/MTX group.ACR20 response at week 24 was signi ficantly greater for ETA monotherapy and ETA/MTX combination therapy compared to MTX monotherapy,but combination therapy(ETA/MTX) and ETA monotherapy had similar results.18
Combe et al.27observed a comparable number of PsA patients in the ETA monotherapy and ETA/MTX combination therapy group achieving the PsA response criteria (PsARC;
80% and 83%) and ACR20 (70%,both).Furthermore,a recent study by Behrens et al.reported that a comparable proportion of PsA patients with ETA monotherapy and ETA/csDMARDs combination therapy showed treatment response.28Treatment response was measured against three treatment goals:(1)Achieving low disease activity based on the DAS28 value,(2) involved body surface area ≤ 3% and (3) short form-12 score > 45.After 52 weeks,24.3% (monotherapy) and 24.5%(combination therapy) achieved all three treatment goals.The combination of ETA and csDMARD did not improve clinical response compared to ETA monotherapy.28
INFLIXIMAB AND GOLIMUMAB
Subgroup analyses of RCTs with INF showed no significant difference in the ACR20 response when MTX was taken simultaneously compared to monotherapy.22,23In a study with PsA patients receiving GOL with/without continued MTX use,MTX did not affect the ACR20 response at week 14.Interestingly,no patient who took MTX at baseline developed antibodies against GOL,while 4.6% of patients without additional MTX did.29
IXEKIZUMAB
Data from the Spirit-P1 study,which included PsA patients receiving ixekizumab/MTX combinational therapy or ixekizumab monotherapy,showed higher ACR20 response rates at week 24 in the ixekizumab group compared to placebo,regardless of MTX concomitant therapy.30A larger proportion of patients in the ixekizumab group reported adverse events compared to the placebo group,and again,this was regardless of MTX concomitant therapy.30
USTEKINUMAB AND SECUKINUMAB
A subgroup analysis of the PSUMMIT 1 study,which included PsA patients receiving UST/MTX combinational therapy or UST monotherapy,reported numerically lower ACR20 response rates at week 24 for patients with combinational therapy(UST/MTX) compared to monotherapy,but significance tests were not performed.31The numerically lower response rates were only observed in the 90 mg UST groups,but not in the 45 mg UST groups.ACR20 response in the 90 mg UST group was ~41% at week 24 for the UST/MTX combinational therapy and ~52% for the UST monotherapy.With 45 mg UST both groups (UST/MTX and UST) showed a ~40% ACR20 response rate at week 24 (data were only shown graphically in the supplementary material).31The number of patients with adverse events was independent of MTX use.31
A subgroup analysis of the FUTURE 2 study,which included PsA patients receiving secukinumab/MTX combinational therapy or secukinumab monotherapy,suggested that improvements in ACR response rates at week 24 occurred independent of concomitant MTX use.32
APREMILAST
In a subgroup analysis of a phase II placebo-controlled study with PsA patients receiving either apremilast/MTX combinational therapy or apremilast monotherapy,no signi ficant differences in the ACR20 response rate were observed between combinational therapy and monotherapy.33
DRUG SURVIVAL
TNFi therapy might be improved due to a greater drug survival (i.e.how long patients maintain a therapy) with concomitant MTX use in in flammatory arthritis,including PsA.In RA,immunogenicity may play a role in reduced drug concentrations and efficacy:the formation of antidrug antibodies in response to monoclonal antibodies may result in low serum drug concentrations,loss of therapeutic response,and poor drug survival.12Therefore,concomitant MTX might reduce the frequency of anti-drug antibody formation in the treatment of inflammatory arthritis.
Concomitant MTX therapy in PsA was associated in two studies (261 and 172 PsA patients) with an increased drug survival of TNFi therapy and was associated with significantly fewer therapy discontinuations due to adverse events during the study.21,34In addition,data from the Danish DANBIO registry with 764 PsA patients receiving TNFi/MTX combinational therapy or TNFi monotherapy showed that concomitant MTX at baseline was associated with a longer drug survival.35This result could not be reproduced in the 2016 data analysis of a non-interventional study from Germany in which data from 1455 PsA patients (ADA with/without MTX) and another study with 82 PsA patients (ETA with/without MTX) were examined.26,36Also,data from the CORRONA registry with 519 PsA patients with TNFi/MTX combinational therapy or TNFi monotherapy showed no difference in drug survival.37In the British Society for Rheumatology Biologics Register,patients (596 PsA patients) treated with INF/MTX and ADA/MTX showed a better drug survival compared to monotherapy,whereas patients treated with ETA/MTX showed no difference in drug survival compared to monotherapy.38In the PROVE observational study,the use of MTX did not significantly affect drug survival over 5 years in ETA-treated PsA patients.39In the IMPACT 2 trial,which evaluated the efficacy of INF in PsA,only 3.6% of patients receiving MTX were positive for anti-INF antibodies,while 26.1% of patients not receiving MTX tested positive for anti-INF antibodies.40Concomitant MTX has also been associated with lower incidence of anti-drug antibodies to GOL in PsA patients.29
Figure1:MUST study:overview of study design.
Anti-drug antibodies against INF and ADA in combination with low trough level of the drug correlate with lower response rates,while concomitant MTX use reduced the formation of anti-drug antibodies.27However,antibodies against the fusion receptor protein ETA are rarely detected.41Overall,this suggests that potentially positive effects of MTX concomitant therapy are most likely to be expected with monoclonal antibodies.A meta-analysis evaluating the immunogenicity in inflammatory arthritis including PsA reported that the use of immunosuppressants,primarily MTX,reduced the proportion of patients receiving INF and ADA with detectable anti-drug antibodies by about 41%.42
MUST STUDY
The data available so far indicate that MTX does not signif icantly improve the clinical efficacy of biologic therapy in PsA patients.It remains unclear whether and to what extent MTX alters drug survival by influencing the formation of neutralizing antibodies,whether MTX naive patients benefit more from the combination of MTX and biologic therapy than from biologic monotherapy,and whether MTX patients receiving biologic therapy deteriorate when MTX is discontinued.
The MUST study (“Impact of concomitant methotrexate on efficacy,safety and adherence of ustekinumab-treatment in patients with active psoriatic arthritis”) is an Investigator Initiated,German multicenter,randomized clinical trial in patients with active PsA to investigate the impact of placebo-controlled MTX therapy combined with initiated biologic therapy with UST (interleukin 12/23 inhibitor) on efficacy,safety and adherence (Figure1).In addition,the MUST study evaluates whether the disease activity of patients who are already taking MTX and who are initiating UST therapy will worsen when MTX is discontinued (EudraCT No.2015-005777-20).
UST is a fully human monoclonal antibody targeting the p40 subunit shared by IL-12 and IL-23.The cytokines interleukin(IL)-12 and IL-23 are involved in the pathogenesis of psoriasis and PsA.UST prevents the binding of IL-12 and IL-23 to their receptors and blocks the Th1 and Th17 inflammatory pathways.UST was investigated for the treatment of various chronic immune-mediated diseases such as psoriasis and PsA.Most data on the safety of UST are derived from experience in the treatment of patients with psoriasis,but clinical studies have demonstrated the efficacy and safety of UST in the treatment of both diseases.43
TNFi must be administered every 1,2 or 4 weeks,whereas UST is administered only every 12 weeks after the two ini-tial doses.This could improve therapy adherence.This is of great importance as the efficacy of drugs in clinical practice depends on whether patients adhere to their medication.A cohort analysis of 1219 patients who received TNFi showed that treatment adherence was 51% with INF,27% with ETA and 23% with ADA.44
The primary objective of the MUST study is to demonstrate that UST monotherapy is not inferior to MTX/UST combination therapy in the mean DAS28 at week 24.In total,196 patients are planned to be enrolled in this study.Currently,163 patients have been included in the MUST study in 28 centers(as of October 28,2019).
Patients with ongoing MTX therapy as well as MTX-naive patients will be included in the clinical trial.Further inclusion criteria are the diagnosis of active PsA (diagnosis according to CASPAR criteria),the presence of ≥ 4 tender joints,≥ 4 swollen joints (from 68/66 joints) and a DAS28 ≥ 3.2.In addition,UST pre-treatment is not allowed.During the study,the following data will be collected to measure efficacy:DAS28,tender joints,swollen joints,ACR20/50/70 response,Psoriasis Area and Severity Index,body surface area,BASDAI,compliance(questionnaire CQR5),quality of life (questionnaires HAQ,EQ5D,DLQI),Leeds enthesitis index,dactylitis,mtNAPSI and ultrasound (PsASon22,selected centers only).Safety data are also collected.Within a biomaterial collection,factors of immunogenicity can later be determined.
According to the MTX pre-therapy,patients are distributed to the treatment arms as follows (Figure1):
Group A:active PsA with MTX at stable dose (15 mg 1×weekly) at study start
Arm 1:UST (45 mg or 90 mg according to product information) + placebo
Arm 2:UST (45 mg or 90 mg according to product information) + MTX (15 mg once a week)
Group B:active PsA without MTX at study start
Arm 1:UST (45 mg or 90 mg according to product information) + placebo
Arm 2:UST (45 mg or 90 mg according to product information) + MTX (15 mg once a week)
The patients are assessed after the baseline examination at week 4,16,24,28,40,52,and 90 days after week 52 (followup telephone visit).The total duration of treatment with UST is 52 weeks (Figure1).
CONCLUSION
The influence of concomitant MTX on the clinical efficacy of biologic therapy in PsA has not yet been sufficiently investigated in a placebo-controlled setting.So far,only one randomized,controlled study regarding the concomitant use of MTX with ETA has been performed and results were recently published.The otherwise available study data,which mainly originate from subgroup analyses,registry data and data from non-interventional studies,cannot be clearly evaluated with regard to the clinical evaluation of combination therapy.Nevertheless,the current data indicate that in PsA,in terms of clinical efficacy,combination therapy with MTX appears to have less clinical significance than in other indications compared to monotherapy.Open questions remain,e.g.,(I)what is the impact of MTX on neutralizing antibody formation and adherence,(II) do MTX naive patients benefit more from the combination of MTX and biologic therapy than from biologic monotherapy,and (III) do MTX patients receiving add-on biologic therapy deteriorate when MTX is discontinued.The MUST study offers the ideal opportunity to answer these questions in a controlled study.
Author contributions
Manuscript writing:SD;
critical revision of the manuscript for intellectual content:MK and FB.All authors approved the final version of the manuscript.
Conflicts of interest
SD,MK,and FB received research support from Janssen-Cilag GmbH,Neuss,Germany.
Financial support
No financial support was received for writing this article.
Copyright license agreement
The Copyright License Agreement has been signed by all authors before publication.
Plagiarism check
Checked twice by iThenticate.
Peer review
Externally peer reviewed.
Open access statement
This is an open access journal,and articles are distributed under the terms of the Creative Commons Attribution-Non Commercial Share A-like 4.0 License,which allows others to remix,tweak,and build upon the work non-commercially,as long as appropriate credit is given and the new creations are licensed under the identical terms.
相关热词搜索:combinational arthritis Psoriatic
- 范文大全
- 说说大全
- 学习资料
- 语录
- 生肖
- 解梦
- 十二星座
-
主题党日活动交流发言8篇
主题党日活动交流发言8篇主题党日活动交流发言篇13月13日,东城区党史学习教育动员大会召开。市委
【活动总结】 日期:2022-12-23
-
2022年4月主题党日活动记录范文15篇
2022年4月主题党日活动记录范文15篇2022年4月主题党日活动记录范文篇1一个崇尚阅读的民族,必然精神饱满、意气风发、活力四射。习近平总书记强调:“学习
【活动总结】 日期:2022-08-01
-
家乡赋|最美的家乡赋
家乡赋 孙传志 今安康市,白河双丰镇,吾之家乡也。三环沃土,山水环抱。其北依山,山系五岭,山
【调研报告】 日期:2020-04-01
-
少先队的光荣历史故事 队前教育-光辉历程
2017-2018学年队前教育1光辉历程一、劳动童子团1924——1927二、三十年代年的中国是一个
【法律文书】 日期:2020-06-23
-
党支部1-12月全年主题党日活动计划表
2022年党支部主题党日活动计划表序号活动时间活动方式活动内容12022年1月专题学习研讨集中观看2022年新年贺词,积极开展学习研讨交流。组织生活会组织党员认真对照党章...
【活动总结】 日期:2022-10-14
-
【人教版1-6年级数学上册知识点精编】1-6年级数学人教版教材
人教版二年级数学上册知识点汇总第一单元长度单位一、米和厘米1、测量物体的长度时,要用统一的标准去测量
【调研报告】 日期:2020-11-08
-
2022年2月份主题党日活动记录5篇
2022年2月份主题党日活动记录5篇2022年2月份主题党日活动记录篇1尊敬的党组织:在今年的开学初,本人积极参加教研室组织的教研活动,在学校教研员的指
【活动总结】 日期:2022-08-12
-
医院最佳主题党日活动11篇
医院最佳主题党日活动11篇医院最佳主题党日活动篇1 医院最佳主题党日活动篇2为隆重纪念中国共产党成立100周年,进一步巩固党的群众路线教育实践活动成果,切实
【活动总结】 日期:2022-10-29
-
2023年平安校园建设方案13篇
平安校园建设方案“平安校园”创建工作,我们幼儿园全体教职员工一直把它当作头等大事来抓。领导高度重视,以“平安校园”创建活动为抓手,建立和规范校园安全工作机制
【规章制度】 日期:2023-11-02
-
主题党日活动记录202210篇
主题党日活动记录202210篇主题党日活动记录2022篇12021年是中国共产党成立100周年,为广泛开展爱国主义宣传教育,铭记党的历史,讴歌党的光辉历程,
【活动总结】 日期:2022-08-02
-
正式的晚宴邀请函 公司晚宴邀请函
尊敬的先生 女士: 我公司谨定于xxxx年xx月xx日xx:xx在xxxx店隆重举行xx市xx届xxxx晚宴(宴会地址:xx区xx路xxxx) 敬请届时光临!xxxxxx集团股份有限公司xxxx有限公司敬邀xxxx年xx月xx日
【简历资料】 日期:2019-08-03
-
一年级新学期目标简短_一年级学生新学期打算
新学期到了,我是一年级下册的小学生了。 上课的时候,我要认真学习,不做小动作,认真听讲。我要认真学习,天天向上,努力学习,耳朵要听老师讲课,眼睛要瞪得大大的看老...
【简历资料】 日期:2019-10-26
-
《国行公祭,为佑世界和平》课文原文阅读_国行公祭为佑世界和平每段段意
国行公祭,为佑世界和平钟声“国行公祭,法立典章。铸兹宝鼎,祀我国殇。”侵华日军南京大屠杀遇难同胞纪念
【简历资料】 日期:2020-11-28
-
[信访复查复核制度作用探讨]信访复查复核有用吗
作为我国特有的一项制度,信访制度的出现并长期存在不是偶然的,虽然一些法学专家认为信访制度具有“人治”
【职场指南】 日期:2020-02-16
-
[党员干部2019年主题教育个人问题检视清单及整改措施2篇] 党员干部
2019年主题教育问题检视清单及整改措施根据主题教育领导小组办公室《关于认真做好主题教育检视问题整改
【求职简历】 日期:2019-11-08
-
网络维护工作内容_(精华)国家开放大学电大专科《网络系统管理与维护》形考任务1答案
国家开放大学电大专科《网络系统管理与维护》形考任务1答案形考任务1理解上网行为管理软件的功能【实训目
【职场指南】 日期:2020-07-17
-
红旗颂朗诵稿原文【《红旗颂》朗诵词】
《红旗颂》朗诵词 女:晴空万里,红旗飘扬, 六十载风云,我们昂首阔步。 男:六十个春秋,
【职场指南】 日期:2020-02-16
-
党委会与局长办公会的区别_局长办公会制度
为进一步加强xxx局工作的规范化、制度化建设,提高行政效能,规范议事程序,特制定本制度。一、会议形式1、局长办公会议由局长、副局长参加。由局长召集和主持。根据工作需要...
【求职简历】 日期:2019-07-30
-
《铁拳砸碎“黑警伞”》警示教育片观后感
影片深刻剖析了广西北海市公安局海西派出所原所长张枭杰蜕变堕落的轨迹。观看警示教育片后,做为一名党员教
【简历资料】 日期:2020-08-17
-
如何凝心聚力谋发展【坚定信心谋发展凝心聚力促跨越】
当前,清河正处于在苏北实现赶超跨越基础上全面腾飞的战略机遇期,处于在全市率先实现全面小康基础上率先实
【简历资料】 日期:2020-03-17
-
追,踪
荒城手机铃声骤然响起的时候,刘陌野看了一眼闹钟,凌晨一点半。老何在电话里简洁又急促地说:“养老院对面
【其他范文】 日期:2023-02-23
-
浅析小学生习作评改的方法
王丽蕴[摘要]随着新课改的推进,习作教学越来越受到重视。习作评改是习作教学的一项重要内容,是习作教学
【其他范文】 日期:2022-12-30
-
[学习心得体会:学习“江山就是人民,人民就是江山”心得体会(二)]
学习“江山就是人民,人民就是江山”心得体会(二)习近平总书记在党史学习教育动员大会上指出:“历史充分
【汇报体会】 日期:2021-07-26
-
医学院校食品专业开放性实验教学体系探究*
丁楠于小磊李婧(锦州医科大学食品与健康学院,辽宁锦州121000)开放性实验跟传统的实验教学模式有所
【其他范文】 日期:2023-01-11
-
2022年同意党支部换届批复范本
当前位置:>>>2021-12-12同意党支部换届批复怎么写?下面是好范文网小编给大家整理收集的同意党支部换届批复范文,供大家阅读参考。同意党支部换届批复范文1中国共产党中华职教...
【其他范文】 日期:2022-11-24
-
三八节书记讲话11篇
三八节书记讲话11篇三八节书记讲话篇1回顾历史,多少次枪林弹雨,多少次艰难险阻,从落后封闭走向进
【其他范文】 日期:2022-12-24
-
清峻亭
■李薇薇人物表邹玉祥——男,60来岁陈桂秋——女,55岁左右,邹玉祥老婆。锤子——男,45岁左右,村
【其他范文】 日期:2023-01-11
-
最新国家开放大学电大《信息化管理与运作》形考任务5试题及答案_
最新国家开放大学电大《信息化管理与运作》形考任务5试题及答案形考任务5判断题(每题1分)。题目1系统
【其他范文】 日期:2020-08-12
-
【2013年学校安全教育日活动总结】 学校安全教育日活动总结
2013年3月26日是全国第17个中小学生安全教育日,这一周被定为安全教育周。我们学校借此机会举行了一系列的活动,加强对学生安全知识的教育,让同学们懂得处处注重安全的重要,...
【汇报体会】 日期:2019-09-02
-
2023年在区委全体会议暨经济工作会议上讲话【完整版】
同志们:在新中国的发展历程中,2021年注定是具有里程碑意义的一年。总揽发展全局,把握潮流大势,中央和省委、市委经济工作会议先后召开,对2021年经济工作对账盘点,对2022年...
【其他范文】 日期:2023-09-27
-
理论中心组学习总体国家安全观发言材料9篇
理论中心组学习总体国家安全观发言材料9篇理论中心组学习总体国家安全观发言材料篇1(八)深入学习贯彻中央以及省的重要会议和文件精神深入学习贯彻年度内中央以
【发言稿】 日期:2022-08-04
-
军转座谈会交流发言4篇
军转座谈会交流发言4篇军转座谈会交流发言篇1大家好,我叫贺丽,2015届选调生,来自康定市委组织部,现在省委编办跟班学习。今天,非常荣幸向大家汇报我的学习收
【发言稿】 日期:2022-10-27
-
12岁生日小寿星发言4篇
12岁生日小寿星发言4篇12岁生日小寿星发言篇1各位来宾、各位朋友:大家好!今天,我们欢聚在这里,共同庆祝**十二周岁生日。首先,我代表**的父母以
【发言稿】 日期:2022-07-31
-
党内警告处分表态发言14篇
党内警告处分表态发言14篇党内警告处分表态发言篇1尊敬的各位领导、同事们:大家上午好!刚才会上宣布了党委关于我任职的决定,我首先衷心感谢党委的信任和
【发言稿】 日期:2022-09-13
-
【企业疫情风险控制方案】 2020企业复工疫情方案
企业疫情风险控制方案2020新冠病毒肺炎疫情防控工作总结汇报3篇 关于新型冠状病毒感染的肺炎疫
【演讲稿】 日期:2020-02-27
-
党内警告处分党员讨论发言3篇
党内警告处分党员讨论发言3篇党内警告处分党员讨论发言篇1大家好!作为新时期的一名大学生,认真学习、深刻领会、全面贯彻省党代会精神,是当前和今后一个时期重
【发言稿】 日期:2022-08-07
-
廉政大会总结发言稿7篇
廉政大会总结发言稿7篇廉政大会总结发言稿篇1各位领导,同志们:根据会议安排,我就党风廉政建设工作做表态发言,不妥之处,请批评指正。一、提高认识,切实
【发言稿】 日期:2022-10-30
-
被约谈的表态发言8篇
被约谈的表态发言8篇被约谈的表态发言篇1各位领导、各位党员大家好:这天我能站在鲜红的党旗下,
【发言稿】 日期:2022-12-24
-
破冰提能大讨论个人发言4篇
破冰提能大讨论个人发言4篇破冰提能大讨论个人发言篇1党史学习教育开展以来,我坚持读原著、学原文、悟原理。今天,根据会议安排,现在我就“学史明理”主题谈几点个
【发言稿】 日期:2022-10-09
-
巡察整改专题民主生活会总结发言8篇
巡察整改专题民主生活会总结发言8篇巡察整改专题民主生活会总结发言篇1按照区委统一部署和纪监委、巡察办关于召开党史学习教育专题组织生活会的工作安排,近期我紧贴
【发言稿】 日期:2022-10-12
-
2023年中国行政区划调整方案(设想优秀3篇
中国行政区划调整方案(设想优秀民政部第二次行政区划研讨会会议内容一、缩省的意义与原则1.意义1)利于减少中间层次中国行政区划层级之多为世界之最,既使管理成本
【周公解梦】 日期:2024-02-20
-
学习周永开先进事迹心得体会3篇
学习周永开先进事迹心得体会【一】通过学习周永开老先生先进事迹后,结合自己工作思考,感慨万千。同样作为
【格言】 日期:2021-04-10
-
2023年和儿媳妇在一起幸福的句子3篇
和儿媳妇在一起幸福的句子1、假如人生不曾相遇,我还是那个我,偶尔做做梦,然后,开始日复一日的奔波,淹没在这喧嚣的城市里。我不会了解,这个世界还有这样的一个你
【格言】 日期:2023-11-10
-
最满意的三项工作200字【最新党办公务员副主任提拔考察个人三年思想工作总结报告】
党办公务员个人三年工作总结近三年来,本人在组织、领导的关心指导和同事们的团结协作下,尽快完成主角的转
【格言】 日期:2021-02-26
-
XX老干局推进党建与业务深度融合发展工作情况调研报告:党建调研报告
XX老干局推进党建与业务深度融合 发展工作情况的调研报告 党建工作与业务工作融合发展始终是一个充满生
【成语大全】 日期:2020-08-28
-
中国共产党第三代中央领导集体的卓越贡献
中国共产党第三代中央领导集体的卓越贡献 --------------继往开来铸就辉煌 【摘要】改
【成语大全】 日期:2020-03-20
-
信息技术2.0能力点 [全国中小学教师信息技术应用能力提升工程试题题库及参考答案「精编」]
全国中小学教师信息技术应用能力提升工程试题题库及答案(复习资料)一、判断题题库(A为正确,B为错误)
【格言】 日期:2020-11-17
-
党建工作运行机制内容有哪些_构建基层党建工作运行机制探讨
党的基层组织是党在社会基层组织中的战斗堡垒,是党的全部工作和战斗力的基础。加强和改进县级以下各类党的
【经典阅读】 日期:2020-01-22
-
电大现代教育原理_最新国家开放大学电大《现代教育原理》形考任务2试题及答案
最新国家开放大学电大《现代教育原理》形考任务2试题及答案形考任务二一、多项选择题(共17道试题,共3
【成语大全】 日期:2020-07-20
-
集合推理_七,推理与集合
七推理与集合1 期中考试数学成绩出来了,三个好朋友分别考了88分,92分,95分。他们分别考了多少分
【名人名言】 日期:2020-12-18
-
关于三农工作重要论述心得体会3篇
关于三农工作重要论述心得体会3篇关于三农工作重要论述心得体会篇1习近平总书记指出:“建设现代化国家离不开农业农村现代化,要继续巩固脱贫攻坚成果,扎实推进乡村
【学习心得体会】 日期:2022-10-29
-
【福生庄隧道坍塌处理方案】 福生庄隧道在哪里
(呼和浩特铁路局大包电气化改造工程指挥部,内蒙古呼和浩特010050)摘要:文章介绍了福生庄隧道
【学习心得体会】 日期:2020-03-05
-
五个一百工程阅读心得体会13篇
五个一百工程阅读心得体会13篇五个一百工程阅读心得体会篇1凡益之道,与时偕行。在全国网络安全和信
【学习心得体会】 日期:2022-12-07
-
城管系统警示教育心得体会9篇
城管系统警示教育心得体会9篇城管系统警示教育心得体会篇1各党支部要召开多种形式的庆七一座谈会,组织广大党员进行座谈,回顾党的光辉历程,畅谈党的丰功伟绩,
【学习心得体会】 日期:2022-10-09
-
发展对象培训主要内容10篇
发展对象培训主要内容10篇发展对象培训主要内容篇1怀着无比激动的心情,我有幸参加了__新区区委党校20__年第四期(区级机关)党员发展对象培训班。这次的学习
【培训心得体会】 日期:2022-09-24
-
扶眉战役纪念馆心得体会11篇
扶眉战役纪念馆心得体会11篇扶眉战役纪念馆心得体会篇1有那么一段历史,低诉着血和泪的故事,慢慢地,随岁月老去;有那么一群人,放弃了闲逸的人生,辗转奔波中
【学习心得体会】 日期:2022-08-03
-
2022年全国检察长会议心得7篇
2022年全国检察长会议心得7篇2022年全国检察长会议心得篇1眼睛是心灵上的窗户,我们通过眼睛才能看到世间万物,才能看到眼前这美好的一切。拥有一双明亮的眼
【学习心得体会】 日期:2022-10-31
-
凝聚三种力量发展全过程人民民主心得体会12篇
凝聚三种力量发展全过程人民民主心得体会12篇凝聚三种力量发展全过程人民民主心得体会篇1新民主主义革命是指在帝国主义和无产阶级革命时代,殖民地半殖民地国家中的
【学习心得体会】 日期:2022-08-31
-
全面从严治党的心得体会800字7篇
全面从严治党的心得体会800字7篇全面从严治党的心得体会800字篇1中国特色社会主义是我们党领导
【学习心得体会】 日期:2022-12-14
-
教师全国两会精神学习专题研讨交流材料6篇
教师全国两会精神学习专题研讨交流材料6篇教师全国两会精神学习专题研讨交流材料篇1通过对两会精神深入系统的学习,作为新一代的青年人,更应该严格要求自己,贯彻落
【教师心得体会】 日期:2022-08-11
-
2024年主题教育民主生活会批评与自我批评意见(38条)(范文推荐)
2023年主题教育民主生活会六个方面个人检视、相互批评意见:1 理论学习系统性不强。学习习近平新时代中国特色社会主义思想不深不透,泛泛而学的时候多,深学细照的时候少,特...
【邓小平理论】 日期:2024-03-19
-
2024年交流发言:强化思想理论武装,增强奋进力量(完整)
习近平总书记指出:“一个民族要走在时代前列,就一刻不能没有理论思维,一刻不能没有思想指引。”党的十八大以来,伴随着新时代中国特色社会主义思想在实践中形成发展的历程...
【三个代表】 日期:2024-03-19
-
2024年度镇年度县乡人大代表述职评议活动总结
xx镇20xx年县乡人大代表述职评议活动总结为响应县级人大常委会关于开展县乡两级人大代表述职评议活动,进一步激发代表履职活力,加强代表与人民群众的联系,提高依法履职水平...
【马克思主义】 日期:2024-03-19
-
“千万工程”经验学习体会(研讨材料)
“千万工程”是总书记在浙江工作时亲自谋划、亲自部署、亲自推动的一项重大决策,也是习近平新时代中国特色社会主义思想在之江大地的生动实践。20年来,“千万工程”先后经历...
【三个代表】 日期:2024-03-19
-
2024年在市政协机关工作总结会议上讲话
同志们:刚才,XX同志对市政协机关20XX年工作进行了很好的总结,很精炼,很到位,可以感受到去年机关工作确实可圈可点。XX同志宣读了表彰决定,机关优秀人员代表、先进集体代...
【邓小平理论】 日期:2024-03-18
-
在全区防汛防涝动员暨河长制工作推进会上讲话提纲【完整版】
区长,各位领导,同志们:汛期已经来临,我区城区防涝工作面临强大考验,形势不容乐观。年初,区城区防涝排渍指挥部已经召开专题调度会,修订完善应急预案,建立网格化管理机...
【马克思主义】 日期:2024-03-18
-
2024年镇作风整治工作实施方案(完整文档)
XX镇作风整治工作实施方案为深入贯彻落实党的二十大精神及省市区委深化作风建设的最新要求,突出重点推进干部效能提升,坚持不懈推动作风整治工作纵深发展,根据《关于印发《2...
【毛泽东思想】 日期:2024-03-18
-
2024市优化法治化营商环境规范涉企行政执法实施方案【优秀范文】
xx市优化法治化营商环境规范涉企行政执法实施方案为持续优化法治化营商环境,激发市场主体活力和社会创造力,规范行政执法行为,创新行政执法方式,提升行政执法质效,着力解...
【毛泽东思想】 日期:2024-03-18
-
2024年度关于开展新一轮思想状况摸底排查工作通知(完整)
关于开展新一轮思想状况摸底排查工作的通知为深入贯彻落实关于各地开展干部职工思想状况大摸底大排查情况上的批示要求和改革教育第二次调度会议精神,有针对性做好队伍教育管...
【三个代表】 日期:2024-03-18
-
2024年公路养护中心主任典型事迹材料(完整文档)
“中心的工作就是心中的事业”——公路养护中心主任典型事迹材料**,男,1976年6月出生,1993年参加工作,2000年4月调入**区交通运输局工作,大学本科学历,中共党员,现任**...
【马克思主义】 日期:2024-03-17